Enlivex Therapeutics Ltd. — Proxy Solicitation & Information Statement 2021

Sep 30, 2021

6-K 1 ea148042-6k_enlivex.htm REPORT OF FOREIGN PRIVATE ISSUER

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2021

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Annual and Extraordinary General Meeting of Shareholders

On September 30, 2021, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “ Company ”), announced that it will hold its 2021 Annual and Extraordinary General Meeting of Shareholders of the Company (the “ Annual Meeting ”) on Thursday, November 4, 2021, beginning at 12:00 p.m., Eastern Standard Time, at the offices of the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618 . Copies of the proxy statement (the “ Proxy Statement ”) and the related proxy card are attached to this Report on Form 6-K as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.

Exhibit No.
99.1	Enlivex Therapeutics Ltd. Proxy Statement for the Annual Meeting to be held on November 4, 2021.
99.2	Form of Enlivex Therapeutics Ltd. Proxy Card.

Field: Page; Sequence: 2

Field: Sequence; Type: Arabic; Name: PageNo 1 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Enlivex Therapeutics Ltd.
(Registrant)
By:	/s/ Oren Hershkovitz
Name:	Oren Hershkovitz
Title:	Chief Executive Officer

Date: September 30, 2021

2

Field: Rule-Page

Field: /Rule-Page